Skip to main content

A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma

Trial Status: In Review

This is a phase 1 / 2 study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.

Inclusion Criteria

  • Age ≥ 12 years at the time of informed consent
  • Bodyweight ≥ 40 kg
  • Histologically documented relapsed or metastatic osteosarcoma.
  • Must have measurable disease according to RECIST Guideline version 1.1 criteria.
  • Adequate hematologic and organ function.
  • Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception per institutional standard prior to the first dose and for 6 months after study treatment discontinuation.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

  • Unresolved toxicity of Grade >1 attributed to prior therapies (excluding: Grade ≤2 neuropathy, alopecia, or skin pigmentation)
  • Prior therapy with a WEE1 inhibitor
  • A serious illness or medical condition(s).
  • Pregnant or lactating females. Females of childbearing potential with a positive serum pregnancy test <14 days to Day 1.
  • Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.
  • 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of >470 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.
  • History or current evidence of congenital or family history of long QT syndrome or Torsades de Pointes (TdP).
  • Taking medications with a known risk of TdP.
  • Administration of strong and moderate CYP3A4 inhibitors/inducers and strong and moderate P-gp inhibitors.


Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Contact: Anna Zheng
Phone: 310-794-0129


M D Anderson Cancer Center


Fred Hutch / University of Washington Cancer Consortium

This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical

activity and safety, pharmacodynamics, and pharmacokinetics of ZN-c3 in combination with

gemcitabine in relapsed or refractory osteosarcoma.

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
K-Group Beta

  • Primary ID ZN-c3-003
  • Secondary IDs NCI-2021-03407
  • ID NCT04833582